Progress for European sites in Episurf Medical’s Episealer® knee implant IDE study
Episurf Medical (NASDAQ: EPIS B) today announces that the company has secured ethics approval for all European hospitals that are being prepared to take part in the company’s clinical study “EPIC-Knee: Episealer® Knee System IDE Clinical Study”. This includes approval from ethics committees in the UK (four sites), Germany (two sites) and Denmark (one site). Approval from the respective ethics committee is mandatory for the sites to initiate enrollment of patients into the study. "This is great progress for our IDE study. The randomised, controlled study includes hospitals in both the US